دورة المؤشرنت للتحليل الفني
50 دينار كويتي
ممكن مشورتكم
- بادئ الموضوع ابوراشد
- تاريخ البدء
ابوراشد
عضو نشط
- التسجيل
- 20 سبتمبر 2003
- المشاركات
- 1,300
هدا الخبر صدر يوم الجمعه مادا يعني لها يا ترى تراى ما اعرف انجليزي ممكن احد يترجمه
SCI CORPORATION (Amex: CVM - News) to its shareholders:
Dear Fellow Shareholders:
A major impact on cancer therapy is achieved when a new treatment
significantly increases the survival of cancer patients. With this goal
in mind, a great deal of work is being conducted to increase the success
rate of surgery, radiation and chemotherapy, but, so far, the results do
not point to a breakthrough. Immunotherapy is designed to mobilize the
immune system in the fight against cancer, but immunotherapy has its
limitations too. We believe that our drug, Multikine(R), is a first in a
new class of drug that works by both enhancing radiation/chemotherapy and
activating the immune response against the cancer. We further believe
that this dual action with Multikine, added to existing first line cancer
therapy, may ultimately allow us to increase the success rate of the
first cancer treatment.
We expect to have multiple peer-reviewed scientific publications of data
from our clinical trials with Multikine published during the next
12 months, including one before the end of this year. These new findings
will help you understand why Multikine immunotherapy is so unique and
different, and holds out so much promise for the treatment of cancer. We
ask you to take the time to read those papers in detail and to ask
yourself the following question: "If I was diagnosed with cancer, would
I want Multikine to be added to my regular treatment?" Of all of the
experts who have reviewed the data for CEL-SCI under a secrecy agreement
to date, everyone said yes. We would, too.
We hope that after the publication of our data the readers will allow
themselves to think differently about the treatment of cancer. A new
approach is needed. We believe that Multikine added to the current first
line therapy may very well provide the breakthrough needed for the
treatment of cancer.
Thank you for supporting us.
Sincerely,
Geert Kersten Maximilian de Clara
Chief Executive Officer President
SCI CORPORATION (Amex: CVM - News) to its shareholders:
Dear Fellow Shareholders:
A major impact on cancer therapy is achieved when a new treatment
significantly increases the survival of cancer patients. With this goal
in mind, a great deal of work is being conducted to increase the success
rate of surgery, radiation and chemotherapy, but, so far, the results do
not point to a breakthrough. Immunotherapy is designed to mobilize the
immune system in the fight against cancer, but immunotherapy has its
limitations too. We believe that our drug, Multikine(R), is a first in a
new class of drug that works by both enhancing radiation/chemotherapy and
activating the immune response against the cancer. We further believe
that this dual action with Multikine, added to existing first line cancer
therapy, may ultimately allow us to increase the success rate of the
first cancer treatment.
We expect to have multiple peer-reviewed scientific publications of data
from our clinical trials with Multikine published during the next
12 months, including one before the end of this year. These new findings
will help you understand why Multikine immunotherapy is so unique and
different, and holds out so much promise for the treatment of cancer. We
ask you to take the time to read those papers in detail and to ask
yourself the following question: "If I was diagnosed with cancer, would
I want Multikine to be added to my regular treatment?" Of all of the
experts who have reviewed the data for CEL-SCI under a secrecy agreement
to date, everyone said yes. We would, too.
We hope that after the publication of our data the readers will allow
themselves to think differently about the treatment of cancer. A new
approach is needed. We believe that Multikine added to the current first
line therapy may very well provide the breakthrough needed for the
treatment of cancer.
Thank you for supporting us.
Sincerely,
Geert Kersten Maximilian de Clara
Chief Executive Officer President
القنوع
عضو نشط
- التسجيل
- 23 يوليو 2003
- المشاركات
- 162
هذه هي الترجمة للخبر:
A major impact on cancer therapy is achieved when a new treatment
significantly increases the survival of cancer patients.
تم إحراز تأثير كبير في علاج السرطان عندما قام العلاج الجديد بزياده عدد الناجين من مرضى السرطان.
With this goal
in mind, a great deal of work is being conducted to increase the success
rate of surgery, radiation and chemotherapy, but, so far, the results do
not point to a breakthrough.
لهذا الهدف, تم توجيه عمل جبار لزيادة النجاح لعمليات الجراحه والعلاج الإشعاعي والعلاج الكيمائي (قصدهم للسرطان), لكن, النتائج لاتؤشر الى تطور هام.
Immunotherapy is designed to mobilize the
immune system in the fight against cancer, but immunotherapy has its
limitations too.
العلاج الناعي تم تصميمه ليعبأ الجهاز المناعي(في الجسم) لمحاربة السرطان, لكن يبقى العلاج المناعي له محدودية هو الآخر.
We believe that our drug, Multikine(R), is a first in a
new class of drug that works by both enhancing radiation/chemotherapy and
activating the immune response against the cancer. We further believe
that this dual action with Multikine, added to existing first line cancer
therapy, may ultimately allow us to increase the success rate of the
first cancer treatment.
نحن مؤمنين بأن عقارنا يعني دواؤنا (ملتي كايين) هو الأول من نوعه لدعم (مسانده) العلاج الأشعاعي والكيمائي كما ينشط إستجابة المناعه ضد الخلايا السرطانيه. كما نؤمن بأن هذه الفعالية المزدوجه لعلاجنا, إضافه لكونه الخط الأول لعلاج السرطان, يدفعنا أخيرا لزيادة معدل النجاح للمعالجه الأولى للسرطان.
البراجراف اللى وراه ما فيه الا حجي مو مهم مثل توقعات ودعوه القراء لقراءه ورقه الدواء كامله. والعياذ بالله يقولون تخيل لو شخصوك على انك مريض سرطان فهل تحب ان يكون هذا الدواء في قائمة ادويتك.
وسامحني على القصور
A major impact on cancer therapy is achieved when a new treatment
significantly increases the survival of cancer patients.
تم إحراز تأثير كبير في علاج السرطان عندما قام العلاج الجديد بزياده عدد الناجين من مرضى السرطان.
With this goal
in mind, a great deal of work is being conducted to increase the success
rate of surgery, radiation and chemotherapy, but, so far, the results do
not point to a breakthrough.
لهذا الهدف, تم توجيه عمل جبار لزيادة النجاح لعمليات الجراحه والعلاج الإشعاعي والعلاج الكيمائي (قصدهم للسرطان), لكن, النتائج لاتؤشر الى تطور هام.
Immunotherapy is designed to mobilize the
immune system in the fight against cancer, but immunotherapy has its
limitations too.
العلاج الناعي تم تصميمه ليعبأ الجهاز المناعي(في الجسم) لمحاربة السرطان, لكن يبقى العلاج المناعي له محدودية هو الآخر.
We believe that our drug, Multikine(R), is a first in a
new class of drug that works by both enhancing radiation/chemotherapy and
activating the immune response against the cancer. We further believe
that this dual action with Multikine, added to existing first line cancer
therapy, may ultimately allow us to increase the success rate of the
first cancer treatment.
نحن مؤمنين بأن عقارنا يعني دواؤنا (ملتي كايين) هو الأول من نوعه لدعم (مسانده) العلاج الأشعاعي والكيمائي كما ينشط إستجابة المناعه ضد الخلايا السرطانيه. كما نؤمن بأن هذه الفعالية المزدوجه لعلاجنا, إضافه لكونه الخط الأول لعلاج السرطان, يدفعنا أخيرا لزيادة معدل النجاح للمعالجه الأولى للسرطان.
البراجراف اللى وراه ما فيه الا حجي مو مهم مثل توقعات ودعوه القراء لقراءه ورقه الدواء كامله. والعياذ بالله يقولون تخيل لو شخصوك على انك مريض سرطان فهل تحب ان يكون هذا الدواء في قائمة ادويتك.
وسامحني على القصور
ابوراشد
عضو نشط
- التسجيل
- 20 سبتمبر 2003
- المشاركات
- 1,300
اولن مشكور اخوى القنوع على الترجمة الله يجزاك خير والله يرحم والديك
الخبر ااقوى ام الشارت؟؟؟؟؟؟؟؟؟؟
صعود فى السعر والا نزول فى السعر والا خبر عادى شكلى مقفل بس والله سهران والضاهر خلايا المخ نامت وخلت اولى من غير فهم عجزت استوعب
شرح مفصل الله يرحم والديك مشكورا لا مامورا
الخبر ااقوى ام الشارت؟؟؟؟؟؟؟؟؟؟
صعود فى السعر والا نزول فى السعر والا خبر عادى شكلى مقفل بس والله سهران والضاهر خلايا المخ نامت وخلت اولى من غير فهم عجزت استوعب
شرح مفصل الله يرحم والديك مشكورا لا مامورا
دورة المؤشرنت للتحليل الفني
50 دينار كويتي